ZDHHC7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2180502	1.00	2/20
SCHEMBL1566194	0.96	2/20
SCHEMBL873757	0.85	2/20
SCHEMBL1415798	0.80	2/20
SCHEMBL719382	0.73	2/20
SCHEMBL1007430	0.72	2/20
SCHEMBL1566554	0.69	2/20
SCHEMBL1415492	0.63	2/20
SCHEMBL97565	0.62	2/20
SCHEMBL337479	0.62	2/20
SCHEMBL337934	0.62	2/20
SCHEMBL338115	0.62	2/20
SCHEMBL338237	0.62	2/20
SCHEMBL338250	0.62	2/20
SCHEMBL375050	0.62	2/20
SCHEMBL817063	0.62	2/20
SCHEMBL844558	0.60	2/20
SCHEMBL1415620	0.58	2/20
SCHEMBL1470910	0.58	2/20
SCHEMBL960248	0.52	2/20

Clinical trials — most relevant to ZDHHC7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate	PHASE4	NOT_YET_RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Omega-3 Fatty Acids for Smoking Cessation in Pregnancy	PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease	nan	NOT_YET_RECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
for Adipose Tissue DIabetes VAriants (fATDIVA)	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Gene Expression in Obesity and Insulin Resistance	nan	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile	nan	WITHDRAWN
Epidemiology of Atherosclerosis	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Genetic Origin of Lipid Disorders	nan	UNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Familial Partial Lipodystrophy Study	nan	COMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Acute Fatty Acid Intervention Study (AFAST)	nan	COMPLETED
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Gene Expression and Inflammation in Overweight Subjects	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Genetic Epidemiology of Hypertriglyceridemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ZDHHC7 binder may also engage these)

Protein	Name	Similarity
Q6DHI1	—	0.998	Q6DHI1 →
Q5RB84	—	0.998	Q5RB84 →
Q923G5	—	0.998	Q923G5 →
Q91WU6	—	0.997	Q91WU6 →
Q94C49	—	0.995	Q94C49 →
Q93VV0	—	0.994	Q93VV0 →
F1QGD2	—	0.994	F1QGD2 →
Q96MV8	—	0.993	Q96MV8 →
F1RE57	—	0.993	F1RE57 →
Q500Z2	—	0.993	Q500Z2 →
Q8VYP5	—	0.993	Q8VYP5 →
Q8R173	—	0.993	Q8R173 →
B1H1H3	—	0.992	B1H1H3 →
Q9D270	—	0.992	Q9D270 →
Q2TGK3	—	0.992	Q2TGK3 →
Q7XA86	—	0.992	Q7XA86 →
Q6FW70	—	0.992	Q6FW70 →
E7F587	—	0.991	E7F587 →
ZDHHC20	Palmitoyltransferase ZDHHC20	0.991	landscape →
A2VDT6	—	0.991	A2VDT6 →
Q9NYG2	—	0.990	Q9NYG2 →
F1QXD3	—	0.990	F1QXD3 →
Q5M757	—	0.990	Q5M757 →
F1QHM7	—	0.990	F1QHM7 →
Q6CQB5	—	0.990	Q6CQB5 →
F1QAM1	—	0.990	F1QAM1 →
Q0VC89	—	0.990	Q0VC89 →
A0A0R4IF99	—	0.990	A0A0R4IF99 →
Q9CPV7	—	0.990	Q9CPV7 →
Q5BLG4	—	0.989	Q5BLG4 →